Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
Delayed Swiss Exchange  -  11:30 2022-10-04 am EDT
332.75 CHF   +3.31%
01:00aRoche to present new data from its expanding neuromuscular disease portfolio at World Muscle Society 2022
AQ
10/04Global Market Rally Pushes European Stocks Higher; Stoxx 600 Gains More Than 3%
MT
10/04ROCHE HOLDINGS AG : Deutsche Bank reiterates its Neutral rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ROCHE HOLDINGS AG : UBS remains Neutral

07/21/2022 | 07:45am EDT

Initially Neutral on the company, UBS's analyst Michael Leuchten maintained his recommendation. The target price is unchanged and still at CHF 328.


© MarketScreener with dpa-AFX Analyser 2022
All news about ROCHE HOLDING AG
01:00aRoche to present new data from its expanding neuromuscular disease portfolio at World M..
AQ
10/04Global Market Rally Pushes European Stocks Higher; Stoxx 600 Gains More Than 3%
MT
10/04ROCHE HOLDINGS AG : Deutsche Bank reiterates its Neutral rating
MD
10/04ROCHE HOLDINGS AG : JP Morgan remains Neutral
MD
10/04Switzerland's Roche Secures US FDA Nod for Breast Cancer Drug Enhertu's Companion Diagn..
MT
10/04Roche receives FDA approval for first companion diagnostic to identify patients with HE..
GL
10/03Roche names Sause head of diagnostics arm
RE
10/03Roche Announces Management Changes
CI
10/03Roche Launches Its Next-Generation SARS-CoV-2 Rapid Antibody Test
CI
10/03Roche Announces Executive Changes
CI
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2022 63 990 M 65 317 M 65 317 M
Net income 2022 14 840 M 15 147 M 15 147 M
Net Debt 2022 11 189 M 11 421 M 11 421 M
P/E ratio 2022 17,8x
Yield 2022 2,90%
Capitalization 273 B 279 B 279 B
EV / Sales 2022 4,45x
EV / Sales 2023 4,30x
Nbr of Employees 100 920
Free-Float 89,0%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 332,75 CHF
Average target price 375,85 CHF
Spread / Average Target 13,0%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Levi A. Garraway Chief Medical Officer
Pascale Schmidt Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-15.04%279 092
JOHNSON & JOHNSON-3.19%429 082
ELI LILLY AND COMPANY16.41%305 529
PFIZER, INC.-24.71%247 729
ABBVIE INC.2.16%244 563
NOVO NORDISK A/S5.25%231 486